3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gastrointestinal
1
Breast
1
Conditions
Breast Neoplasms
166
Triple Negative Breast Neoplasms
54
Neoplasm Metastasis
23
Pancreatic Neoplasms
16
Carcinoma, Non-Small-Cell Lung
15
Ovarian Neoplasms
11
Colorectal Neoplasms
9
Small Cell Lung Carcinoma
8
Sarcoma
8
Neoplasms
8
Lung Neoplasms
8
Prostatic Neoplasms
7
Colonic Neoplasms
7
Breast Neoplasms, Male
7
Stomach Neoplasms
5
Squamous Cell Carcinoma of Head and Neck
5
Parkinson Disease 4, Autosomal Dominant Lewy Body
5
Lymphoma, Non-Hodgkin
5
Cholangiocarcinoma
5
Head and Neck Neoplasms
4
Urinary Bladder Neoplasms
3
Recurrence
3
Rectal Neoplasms
3
Multiple Myeloma
3
Melanoma
3
Kidney Neoplasms
3
Fallopian Tube Neoplasms
3
Endometrial Neoplasms
3
Carcinoma, Renal Cell
3
Uterine Cervical Neoplasms
2
Interventions
pembrolizumab
1
entinostat
1
anetumab ravtansine
1
Psychiatric Rehabilitation
1
Imatinib Mesylate
1
Gemcitabine
1
Fentanyl
1
Early Intervention, Educational
1
Cisplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Thymoma
×
Gemcitabine
×
Breast
×
Clear all
NCT03102320
2022-06-30
ARCS-Multi
Bayer
Phase 1
Completed
173 enrolled